MedAustron selected C-RAD Catalyst PT

MedAustron selected C-RAD Catalyst PT

C-RAD announced today that it signed a purchasing agreement with MedAustron – the first Ion-therapy treatment site in Austria. The agreement entails the acquisition of C-RAD’s most advanced surface tracking technology and a service agreement.

C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy – Catalyst PT. It is based on the patented Catalyst technology and software as well as the hardware are tailored for the application in this environment. MedAustron went through a public procurement process and at its end the tender was awarded to C-RAD.

The installation of the C-RAD motion management solution will follow a phased approach, whereas the Catalyst PT system will be installed in one of the treatment rooms in the first stage. In further steps the system will be integrated into the existing treatment control system to optimize workflows and usability within particle therapy. The solution that is going to be delivered to MedAustron is a platform, that allows customers to seamlessly integrate motion management into particle treatment systems from various providers and vendors.

Priv. Doz. DI Markus Stock, PhD, Head of Medical Physics at MedAustron adds:

"Strategies for coping with organ motions are crucial for a successful irradiation of certain tumor entities. Whereas our in-room equipment already features precise positioning, position verification and monitoring, the implementation of Catalyst PT will enhance our system significantly by expanding it with tools for motion management."

MedAustron, the center for ion therapy and research is located in Wiener Neustadt in Lower Austria, about 50 kilometers south of Vienna. It is the first center for particle therapy in Austria, and currently treats patients using a proton beam. Besides clinical operation, also non-clinical research in the areas of radiation oncology, medical physics and radiation biology is conducted at MedAustron.

Prof. Dr. Eugen B. Hug, clinical director co-managing director of MedAustron, says: "We look forward to addressing the issue of organ motion management together with C-RAD. The decision was made in favor of their Catalyst PT system, because they best met our requirements and because they demonstrated flexibility with regard to the development of customized features.”

As the workflows that are develop for the application can be deployed on a broad scale to customers in the fast-growing particle therapy segment, this project brings future value for C-RAD.

The agreement has total value of approximately 4,9 MSEK. Delivery is expected to start in December 2018 and finalized in Q3 2019. The product sales as well as the five-year service contract are booked as order intake in the third quarter 2018.

"Within particle therapy accurate patient positioning and motion management are crucial to deploy the potential benefit that this treatment technique offers. At the same time there is a high interest to optimize patient throughput due to high investments required to build and operate such facilities.” says Tim Thurn, CEO and President of C-RAD AB, "We are proud to be the vendor of choice for MedAustron. We are convinced that in this project C-RAD can lift its current technology on a new level that will ultimately help to successfully treat patients not only in Austria, but worldwide.”

About MedAustron

MedAustron in Wiener Neustadt, Lower Austria, is one of the world’s most cutting-edge centers for ion therapy and research. Patients benefit from this innovative form of radiation therapy and are currently treated with protons, later also with carbon ions. Worldwide, there are only five centers that offer the combined application of protons and carbon ions. MedAustron is an interdisciplinary and supra-regional Austrian center specialized in using particles for patient treatments, in helping to further develop this new form of treatment, as well as in conducting research with proton and carbon ion beams.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on Nasdaq Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com

For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

Attachment

• PR 20181011 Order MedAustron ENG